Science Explorer Back to mapMap
Discussion
Researcher · Horizon Discovery (United Kingdom) · United Kingdom

Julie A. Wickenden

Julie A. Wickenden publishes mostly in Molecular Biology, Oncology and Cancer Research, on topics such as Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies and CRISPR and Genetic Engineering.

OpenAlex
World rank
#1,678,617
of 7,710,434 ranked researchers
Rank in United Kingdom
#126,735
of 367,258
Works
15
Citations
716
Citations per work
47.7
h-index
6
i10-index 6Top 94% in Molecular Biology
Julie A. Wickenden

What does Julie A. Wickenden research?

Julie A. Wickenden's work is mostly in Biochemistry, Genetics and Molecular Biology (55%), Medicine (34%), Immunology and Microbiology (4%).

Life Sciences: 9 works · 59.0% of their workBiochemistry, Genetics and Molecular Biology: 8 works · 54.5% of their workMolecular Biology: 6 works · 40.9% of their workCancer Research: 2 works · 13.6% of their workImmunology and Microbiology: 1 works · 4.5% of their workImmunology: 1 works · 4.5% of their workHealth Sciences: 5 works · 34.1% of their workMedicine: 5 works · 34.1% of their workOncology: 3 works · 18.2% of their workPulmonary and Respiratory Medicine: 1 works · 9.1% of their workPathology and Forensic Medicine: 1 works · 6.8% of their workEverything else: 1 works · 6.9% of their workTHEIR WORKJulie A.Wickenden15works
Life Sciences59%Health Sciences34%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology854.5%
    2. Immunology and Microbiology14.5%
    1. Medicine534.1%
  3. Everything else16.9%
  1. 1Molecular Biology41% of their works
  2. 2Oncology18% of their works
  3. 3Cancer Research14% of their works
  4. 4Pulmonary and Respiratory Medicine9% of their works
  5. 5Pathology and Forensic Medicine7% of their works
  6. 6Immunology4% of their works

Research topics

Which keywords describe Julie A. Wickenden's research?

The keywords of their largest research topics: Cancer Therapy, Cancer Genomics, Mutational Signatures, Cetuximab, KRAS Mutations, BRAF gene, Cancer Stem Cells and Cell Cycle.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Cancer Therapy63 topics
  2. Cancer Genomics51 topic
  3. Mutational Signatures51 topic
  4. Cetuximab31 topic
  5. KRAS Mutations31 topic
  6. BRAF gene21 topic
  7. Cancer Stem Cells21 topic
  8. Cell Cycle21 topic
  9. Genome Engineering21 topic
  10. MAP Kinase21 topic
  11. Microsatellite Instability21 topic
  12. Molecular Characterization21 topic
  13. Proteasome21 topic
  14. RNA-Guided21 topic
  15. Tumor Metastasis21 topic
  16. Ubiquitin21 topic
  17. p5321 topic

Where does Julie A. Wickenden work?

Julie A. Wickenden's main affiliation in the publication record is Horizon Discovery (United Kingdom), United Kingdom.

How many publications and citations does Julie A. Wickenden have?

OpenAlex counts 15 works and 716 citations for Julie A. Wickenden, an h-index of 6, ranking #1,678,617 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Julie A. Wickenden. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.